NEUROLOGICAL CANCERS IN 2016PUERTO RICO CANCER CONFERENCE SERIES:

THE PONCE SCHOOL OF MEDICINE IN JOINT SPONSORSHIP WITHTHE PUERTO RICAN ASSOCIATION OF RADIATION ONCOLOGISTS INVITES YOU TO:

SATURDAY, AUGUST 27TH, 2016

7:15 A.M. – 4:10 P.M.

CONDADO PLAZA HILTON, SAN JUAN, PR

This activity has been planned and implemented in accordance with the Essentials Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME), through the Ponce School of Medicine & Health Sciences is accredited by the ACCME, provider’s No. 0007249, to provide continuing medical education for physicians. Ponce School of Medicine & Health Sciences is accredited by Puerto Rico Board of Medical Licensure and Discipline, provider’s No. 016-DC17-JLDM.

after orin the event.

for physicians beforeFriday, August 19

PAYMENT METOD

$65.00 $85.00

OBJECTIVESAt the end of this educational activity, the audience should be able to:

• Understand the indications for surgery, radiotherapy and chemo-therapy and the factors influencing the choice of treatment of brain metastases

• Recognize the importance of molecular markers and their relevance in the treatment of high-grade and low-grade gliomas

• Understand new treatment options for glioma patients and the rationale for their use

• Understand the importance of supportive care in brain tumor patients

• Understand the importance of follow-up and the sequelae of treatment in long term survivors of medulloblastoma

INTENDED AUDIENCE This educational activity has benn designed for medical oncologists, neurologists, neuro-oncologists, neurosurgeons, pathologists, radiation oncologists, and other physicians with special interest in the management of neurological cancers.

CREDIT DESIGNATION Ponce School of Medicine & Health Sciences designates this educa-tional activity for a maximum of 8 AMA PRA Category 1 Credits. Physicians should only claim credits commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURE POLICY The Ponce School of Medicine is committed to the independence, balance, objectivity, scientific rigor and integrity in all of the education-al activities it sponsors. Everyone who is in a position to control the content of this educational activity has been instructed to disclose all relevant financial relationship with any commercial interest they and their spouse/partner may have received within the last 12 months that courld be interpreted as a conflict interest.

PRELIMINARY AGENDA 7:10 a.m. - 8:00 a.m. Registration, Breakfast and Exhibitor's Hall 8:00 a.m.- 8:10 a.m. Welcome Remarks 8:10 a.m. - 8:50 a.m. Indications for surgery, radiosurgery, and/or whole brain radiation in the treatment of brain metastases 8:50 a.m. - 9:35 a.m. Evolution of radiotherapy for multiple brain metastases: whole brain IMRT with SIB and hippocampal sparing and ingle-isocenter volumetric modulated arc radiosurgery 9:35 a.m. - 10:20 a.m. Novel chemotherapy and targeted therapy approaches for brain metastases 10:20 a.m. - 10:30 a.m. Brain metastases Q&A 10:30 a.m. - 10:45 a.m. Coffee Break and Exhibitor's Hall 10:45 a.m. - 11:30 a.m. Current neurosurgical management of gliomas 11:30 a.m. - 12:15 p.m. Evolving molecular biology and novel therapeutic insights in gliomas 12:15 p.m. - 1:00 p.m. Supportive care in glioma patients 1:00 p.m. - 1:10 p.m. Glioma Q&A 1:10 p.m. - 1:20 p.m. Message by the American Cancer Society 1:20 p.m. - 2:20 p.m. Lunch 2:20 p.m. - 3:00 p.m. Current strategy and new therapeutic insights in the treatment of medulloblastoma 3:00 p.m. - 3:25 p.m. Advances in radiotherapy for medulloblastoma 3:25 p.m. - 3:50 p.m. Treatment sequelae in long term survivors of medulloblastoma 3:50 p.m. - 4:00 p.m. Medulloblastoma Q&A 4:00 p.m. - 4:10 p.m. Closing Remarks

REGISTRATION For registration, please contact Feliciano Communications to:

(787) 964-6394 FELICIANO@FELICIANOCOMM.COM

SPACE ISLIMITED.

Sponsored By

SAVE THE DATE

8 CREDITS

THE ACTIVITY IS